Immunotherapy targets in MM. (A) Monoclonal antibodies binding to targets present in the extracellular compartment of myeloma cells. Outlined are monoclonal antibody targets under clinical development. (B) Chimeric antigen receptors present on the surface of transformed T cells recognizing cell surface antigens on myeloma cells in an HLA-independent manner presentation. Outlined are current MM CAR target molecules. (C) Checkpoint inhibitors interrupting the T-cell inhibitory pathway. Outlined are the known checkpoint inhibitor target molecules. (D) Synthetic T cell receptors present on the surface of transformed T cells, recognizing targets presented in an HLA-restricted manner. Outlined are known synthetic TCR target molecules being examined in MM. mAbs, monoclonal antibodies.